These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7769376)

  • 41. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan.
    Lin HH; Kao JH; Chang TC; Hsu HY; Chen DS
    J Med Virol; 2003 Apr; 69(4):466-70. PubMed ID: 12601752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B.
    Liu CJ; Chen PJ; Lai MY; Lin FY; Wang T; Kao JH; Chen DS
    Liver Int; 2006 Oct; 26(8):949-55. PubMed ID: 16953835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.
    Chu CM; Liaw YF
    Gastroenterology; 2007 Nov; 133(5):1458-65. PubMed ID: 17935720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver function and hepatitis markers in carriers of hepatitis B virus in New Zealand.
    Hopkirk N; Moyes CD; Lucas CR
    N Z Med J; 2000 Apr; 113(1107):114-6. PubMed ID: 10834277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Counselling for hepatitis B virus carriers.
    Okuda K
    Trop Gastroenterol; 1994; 15(1):3-6. PubMed ID: 7974755
    [No Abstract]   [Full Text] [Related]  

  • 47. Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C.
    Kobayashi M; Akuta N; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Saitoh S; Kobayashi M; Someya T; Sato J; Watabiki S; Miyakawa Y; Kumada H
    J Med Virol; 2006 Jan; 78(1):60-7. PubMed ID: 16299721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up of hepatitis B virus carriers with normal transaminases levels.
    Koçak N; Ozen H; Yüce A; Gürakan F
    Turk J Pediatr; 1998; 40(3):365-72. PubMed ID: 9763900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B e antigen in chronic HBV infection--a villain or a guide?
    Parikh SS; Mehta PJ; Bichile SK
    J Assoc Physicians India; 1995 Apr; 43(4):243-4. PubMed ID: 8713261
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial.
    Bahrami H; Daryani NE; Haghpanah B; Moayyeri A; Moghadam KF; Mirmomen S; Kamangar F
    Am J Gastroenterol; 2005 Apr; 100(4):856-61. PubMed ID: 15784032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Australia antigen, autoantibodies and cell-mediated immune responses in patients with Down's syndrome.
    Campion EC; Wangel AG
    Med J Aust; 1975 Apr; 01(15):468-70. PubMed ID: 125374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prognostic value of AFP in chronic carriers of HBsAg with Down's syndrome].
    Carrascosa D; Casado A; Ramírez MV; Sáez J
    Aten Primaria; 1995 Sep; 16(5):296-7. PubMed ID: 7578846
    [No Abstract]   [Full Text] [Related]  

  • 54. Hepatitis-associated (Australia) antigen and Down's syndrome.
    Higgins GR; Parker CE; Faust JA; Rosenfeld M
    Am J Ment Defic; 1974 Jan; 78(4):426-8. PubMed ID: 4273154
    [No Abstract]   [Full Text] [Related]  

  • 55. [Australia antigen in children with Down's syndrome].
    Korczowski R
    Pol Tyg Lek; 1972 Feb; 27(9):327-9. PubMed ID: 4259782
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunologic characteristics of Down's syndrome.
    Gershwin ME; Crinella FM; Castles JJ; Trent JK
    J Ment Defic Res; 1977 Dec; 21(4):237-49. PubMed ID: 146742
    [No Abstract]   [Full Text] [Related]  

  • 57. Letter: IgA, Down's syndrome and shigellosis.
    Ablin RJ
    Dev Med Child Neurol; 1974 Oct; 16(5):686-7. PubMed ID: 4278642
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunodeficiency in Down's syndrome: relationship between presence of human thyroglobulin antibodies and HBsAg carrier status.
    Ugazio AG; Jayakar SD; Marcioni AF; Duse M; Monafo V; Pasquali F; Burgio GR
    Eur J Pediatr; 1977 Oct; 126(3):139-46. PubMed ID: 144056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucose tolerance in Down's syndrome.
    Sutnick AI; London WT; Gerstley BJ; Coyne VE; Blumberg BS; Lustbader ED
    Res Commun Chem Pathol Pharmacol; 1974 Jul; 8(3):471-80. PubMed ID: 4277496
    [No Abstract]   [Full Text] [Related]  

  • 60. Down's syndrome and immune function.
    Rodriguez de al Nuez AL; Sanchez Dominguez T; Villa-Elizaga I; Subira ML
    Am J Dis Child; 1982 Jan; 136(1):81. PubMed ID: 6459735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.